Scholar Rock announces completion of TOPAZ trial enrollment

Scholar Rock announced today that enrollment of its TOPAZ Phase 2 trial of SRK-015 in patients with Type 2 and Type 3 SMA is complete. SRK-015 is a selective inhibitor of myostatin that has been shown to increase muscle mass and strength in animal models.

For more information, please see the press release from Scholar Rock.